NxStage Medical PE Ratio 2006-2018 | NXTM
Current and historical p/e ratio for NxStage Medical (NXTM) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. NxStage Medical PE ratio as of February 15, 2019 is 0.00.
| NxStage Medical PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2019-02-15 | 29.30 | 0.00 | |
| 2018-09-30 | 27.89 | $-0.08 | 0.00 |
| 2018-06-30 | 27.90 | $-0.23 | 0.00 |
| 2018-03-31 | 24.86 | $-0.22 | 0.00 |
| 2017-12-31 | 24.23 | $-0.22 | 0.00 |
| 2017-09-30 | 27.60 | $-0.21 | 0.00 |
| 2017-06-30 | 25.07 | $-0.07 | 0.00 |
| 2017-03-31 | 26.83 | $-0.07 | 0.00 |
| 2016-12-31 | 26.21 | $-0.07 | 0.00 |
| 2016-09-30 | 24.99 | $-0.09 | 0.00 |
| 2016-06-30 | 21.68 | $-0.12 | 0.00 |
| 2016-03-31 | 14.99 | $-0.17 | 0.00 |
| 2015-12-31 | 21.91 | $-0.24 | 0.00 |
| 2015-09-30 | 15.77 | $-0.28 | 0.00 |
| 2015-06-30 | 14.29 | $-0.36 | 0.00 |
| 2015-03-31 | 17.30 | $-0.40 | 0.00 |
| 2014-12-31 | 17.93 | $-0.40 | 0.00 |
| 2014-09-30 | 13.13 | $-0.40 | 0.00 |
| 2014-06-30 | 14.37 | $-0.37 | 0.00 |
| 2014-03-31 | 12.74 | $-0.31 | 0.00 |
| 2013-12-31 | 10.00 | $-0.30 | 0.00 |
| 2013-09-30 | 13.16 | $-0.26 | 0.00 |
| 2013-06-30 | 14.28 | $-0.22 | 0.00 |
| 2013-03-31 | 11.28 | $-0.25 | 0.00 |
| 2012-12-31 | 11.25 | $-0.26 | 0.00 |
| 2012-09-30 | 13.21 | $-0.30 | 0.00 |
| 2012-06-30 | 16.76 | $-0.36 | 0.00 |
| 2012-03-31 | 19.27 | $-0.37 | 0.00 |
| 2011-12-31 | 17.78 | $-0.39 | 0.00 |
| 2011-09-30 | 20.86 | $-0.44 | 0.00 |
| 2011-06-30 | 20.82 | $-0.51 | 0.00 |
| 2011-03-31 | 21.98 | $-0.58 | 0.00 |
| 2010-12-31 | 24.88 | $-0.66 | 0.00 |
| 2010-09-30 | 19.10 | $-0.72 | 0.00 |
| 2010-06-30 | 14.84 | $-0.77 | 0.00 |
| 2010-03-31 | 11.45 | $-0.87 | 0.00 |
| 2009-12-31 | 8.35 | $-0.94 | 0.00 |
| 2009-09-30 | 6.69 | $-0.96 | 0.00 |
| 2009-06-30 | 5.90 | $-1.07 | 0.00 |
| 2009-03-31 | 2.58 | $-1.12 | 0.00 |
| 2008-12-31 | 2.67 | $-1.24 | 0.00 |
| 2008-09-30 | 4.22 | $-1.50 | 0.00 |
| 2008-06-30 | 3.84 | $-1.71 | 0.00 |
| 2008-03-31 | 4.32 | $-1.82 | 0.00 |
| 2007-12-31 | 15.17 | $-1.85 | 0.00 |
| 2007-09-30 | 14.49 | $-1.75 | 0.00 |
| 2007-06-30 | 12.93 | $-1.55 | 0.00 |
| 2007-03-31 | 13.32 | $-1.58 | 0.00 |
| 2006-12-31 | 8.38 | $-1.61 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $1.954B | $0.394B |
| NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $132.164B | 26.13 |
| Medtronic (MDT) | Ireland | $123.923B | 18.53 |
| Stryker (SYK) | United States | $69.625B | 25.56 |
| Boston Scientific (BSX) | United States | $55.366B | 27.03 |
| Baxter (BAX) | United States | $39.075B | 24.08 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.222B | 16.18 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.659B | 0.00 |
| ResMed (RMD) | United States | $14.394B | 27.30 |
| Canopy Growth (CGC) | Canada | $11.042B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.100B | 51.79 |
| Aurora Cannabis (ACB) | Canada | $7.040B | 50.36 |
| Hill-Rom Holdings (HRC) | United States | $6.974B | 21.57 |
| Perrigo (PRGO) | Ireland | $6.650B | 10.09 |
| Insulet (PODD) | United States | $5.226B | 0.00 |
| ICU Medical (ICUI) | United States | $5.189B | 28.91 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.539B | 0.00 |
| Haemonetics (HAE) | United States | $4.489B | 39.82 |
| Agios Pharmaceuticals (AGIO) | United States | $3.449B | 0.00 |
| Hutchison China MediTech (HCM) | China | $3.417B | 0.00 |
| Neogen (NEOG) | United States | $3.281B | 50.39 |
| NuVasive (NUVA) | United States | $3.013B | 28.03 |
| National Vision Holdings (EYE) | United States | $2.624B | 50.75 |
| Quidel (QDEL) | United States | $2.574B | 23.28 |
| Aphria (APHA) | $2.402B | 106.67 | |
| AtriCure (ATRC) | United States | $1.279B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.231B | 17.70 |
| VAREX IMAGING (VREX) | United States | $1.198B | 23.45 |
| Cardiovascular Systems (CSII) | United States | $1.170B | 840.00 |
| HEXO (HEXO) | $1.156B | 0.00 | |
| MacroGenics (MGNX) | United States | $0.923B | 0.00 |
| Cerus (CERS) | United States | $0.878B | 0.00 |
| PetIQ (PETQ) | United States | $0.837B | 21.68 |
| Surmodics (SRDX) | United States | $0.766B | 111.39 |
| Evolus (EOLS) | United States | $0.747B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.719B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.713B | 22.07 |
| Meridian Bioscience (VIVO) | United States | $0.704B | 20.97 |
| OraSure Technologies (OSUR) | United States | $0.703B | 31.03 |
| Omeros (OMER) | United States | $0.688B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.625B | 20.05 |
| Quanterix (QTRX) | United States | $0.505B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.492B | 24.18 |
| Owens & Minor (OMI) | United States | $0.479B | 5.42 |
| TG Therapeutics (TGTX) | United States | $0.395B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.368B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.334B | 21.65 |
| BioLife Solutions (BLFS) | United States | $0.299B | 404.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.293B | 0.00 |
| Bovie Medical (APYX) | United States | $0.279B | 0.00 |
| Vapotherm (VAPO) | United States | $0.276B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.262B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.242B | 0.00 |
| Zynex (ZYXI) | United States | $0.165B | 15.97 |
| Surface Oncology (SURF) | United States | $0.150B | 0.00 |
| Fonar (FONR) | United States | $0.143B | 7.65 |
| Chembio Diagnostics (CEMI) | United States | $0.119B | 0.00 |
| Chimerix (CMRX) | United States | $0.101B | 0.00 |
| United-Guardian (UG) | United States | $0.091B | 18.98 |
| Female Health (VERU) | United States | $0.084B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.081B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.070B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.063B | 17.33 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.062B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Neurotrope (NTRP) | United States | $0.034B | 0.00 |
| Senestech (SNES) | United States | $0.021B | 0.00 |
| Myomo (MYO) | United States | $0.016B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.013B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.013B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.011B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.007B | 13.57 |
